In the SUSTAIN 6 trial (published in the New England Journal of Medicine), patients receiving semaglutide 1 mg weekly experienced a mean weight loss of approximately 4.3 kg over 104 weeks compared to 0.7 kg with placebo
In most CVOTs involving GLP-1 RA, the drugs reduced the risk of new macroalbuminuria compared to placebo [12, 15], however these trials sampled populations of patients at increased cardiovascular and kidney risk
this form is called acne neonatorum, baby acne
Oral semaglutide at higher doses studied for weight management produced very similar average weight loss over about 64 weeks
Temperature loggers placed on refrigerator doors consistently show fluctuations of 5-10 degrees with each opening, while the center of the middle shelf stays within 1-2 degrees
Why dont we treat aging as any other disease when there are simple, science-backed solutions and lifestyle adjustments we can easily implement? Isman remarks